PT  - JOURNAL ARTICLE
AU  - Adrian Soto-Mota
AU  - Braulio A. Marfil-Garza
AU  - Erick Martínez Rodríguez
AU  - José Omar Barreto Rodríguez
AU  - Alicia Estela López Romo
AU  - Paolo Alberti Minutti
AU  - Juan Vicente Alejandre Loya
AU  - Félix Emmanuel Pérez Talavera
AU  - Freddy José Ávila Cervera
AU  - Adriana Velazquez Burciaga
AU  - Oscar Morado Aramburo
AU  - Luis Alberto Piña Olguín
AU  - Adrian Soto-Rodríguez
AU  - Andrés Castañeda Prado
AU  - Patricio Santillán Doherty
AU  - Juan O Galindo Galindo
AU  - Luis Alberto Guízar García
AU  - Daniel Hernández Gordillo
AU  - Juan Gutiérrez Mejía
TI  - THE LOW-HARM SCORE FOR PREDICTING MORTALITY IN PATIENTS DIAGNOSED WITH COVID-19: A MULTICENTRIC VALIDATION STUDY
AID  - 10.1101/2020.05.26.20111120
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.26.20111120
4099  - http://medrxiv.org/content/early/2020/06/05/2020.05.26.20111120.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.05.26.20111120.full
AB  - - Importance Many COVID-19 prognostic factors for disease severity have been identified and many scores have already been proposed to predict death and other outcomes. However, hospitals in developing countries often cannot measure some of the variables that have been reported as useful.- Objective To assess the sensitivity, specificity, and predictive values of the novel LOW-HARM score (Lymphopenia, Oxygen saturation, White blood cells, Hypertension, Age, Renal injury, and Myocardial injury).- Design The score was designed using data from already published cohorts of patients diagnosed with COVID-19. Afterwards, it was calculated it in 438 consecutive hospital admissions at twelve different institutions in ten different cities in Mexico.- Setting Twelve hospitals in ten different cities in Mexico.- Participants Data from 438 patients was collected. Data from 400 patients (200 deaths and 200 survivors) was included in the analysis.- Exposure All patients had an infection with SARS-CoV-2 confirmed by PCR.- Main Outcome The sensitivity, specificity, and predictive values of different cut-offs of the LOW-HARM score to predict death.- Results Mean scores at admission and their distributions were significantly lower in patients who were discharged compared to those who died during their hospitalization 10 (SD: 17) vs 70 (SD: 28). The overall AUC of the model was 95%. A cut-off > 65 points had a specificity of 98% and a positive predictive value of 96%. More than a third of the cases (36%) in the sample had a LOW-HARM score > 65 points.- Conclusions and relevance The LOW-HARM score measured at admission is highly specific and useful for predicting mortality. It is easy to calculate and can be updated with individual clinical progression.Question Is it possible to predict mortality in patients diagnosed with COVID-19 using easy-to-access and easy-to-measure variables?Findings The LOW-HARM score (Lymphopenia, Oxygen saturation, White blood cells, Hypertension, Age, Renal injury, and Myocardial injury) is a one-hundred-point score that, when measured at admission, had an overall AUC of 95% for predicting mortality. A cut-off of ≥ 65 points had a specificity of 98% and a positive predictive value of 96%.Meaning The LOW-HARM score measured at admission is highly specific and useful for predicting mortality in patients diagnosed with COVID-19. In our sample, more than a third of patients met the proposed cut-off.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/qzunb Funding StatementThis project received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was assessed and approved by the Ethics Committee of the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran on April 29th, 2020 (Reg. No. DMC-3369-20-20-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data will be public. https://docs.google.com/spreadsheets/d/1DH4nmfWi-T55Es-Y0CZYzXAwyibcVe_LQ7GyNwK9YWM/edit?usp=sharing